Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2021-02-16 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Zakończenie badań przedklinicznych w celu ustalenia maksymalnej tolerowanej dawki 1-MNA, kandydata na lek w infekcjach wirusowych - Content (PL)
Regulatory Filings Classification · 92% confidence The document is a formal announcement by the Management Board (Zarząd) of PHARMENA S.A. referencing previous reports (raport bieżący nr 31/2020 and 35/2020) regarding preclinical trials for a drug candidate (1-MNA) against Sars-Cov-2. It details the completion of the first of three preclinical studies on animal models, specifically determining the maximum tolerated dose and the necessity for further studies to establish the effective dose for human clinical trials. This content relates to ongoing research, development, and potential future business impact, which aligns best with a general regulatory announcement or a report detailing significant operational/development milestones. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER), or a formal Audit Report (AR), and it discusses significant operational progress that impacts future prospects, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard operational update, or potentially a Legal/Regulatory update if the trials were mandated, but RNS is the most appropriate general category for such specific, material operational news not covered by other specific codes. Given the context of reporting on research progress and its potential impact, RNS is the most suitable fallback.
2021-02-16 Polish
Podpisanie aneksów do istotnych umów pożyczek - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal announcement by the Management Board ("Zarząd") of Pharmena S.A. regarding the signing of annexes to significant loan agreements with related parties (leading shareholder and management/supervisory board members). The content details the extension of repayment terms and the total amounts involved (0.850M PLN, 0.065M PLN, 0.085M PLN). This type of disclosure, concerning financing activities, capital structure changes, and transactions with related parties, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it specifically details changes to financing agreements, 'CAP' is the most appropriate classification.
2021-02-14 Polish
Zawarcie umowy pożyczki z FPR - Content (PL)
Capital/Financing Update Classification · 99% confidence The document text describes the execution of a liquidity loan agreement (Umowa Pożyczki) between the company (PHARMENA S.A.) and the Polish Development Fund (PFR) under a government program. It details the loan amount (up to 4.55 million PLN), the repayment date (December 31, 2024), the purpose of the funds (financing current operations, working capital, trade payables, salaries, etc.), and the interest margin structure over four years. This transaction directly relates to the company securing financing and changing its capital structure/debt obligations. This fits best under the 'Capital/Financing Update' category (CAP). It is not an earnings release, an annual report, or a general regulatory filing (RNS), as it concerns a specific financing event.
2021-02-09 Polish
Rozpoczęcie badań przedklinicznych w celu ustalenia efektywnej dawki 1-MNA w modelu zwłóknienia płuc - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the Management Board (Zarząd) of PHARMENA S.A. referencing previous reports (raport bieżący) regarding preclinical trials for a drug candidate (1-MNA) against Sars-Cov-2. It details the commencement of the final planned preclinical study on animal models, conducted by Covance Inc., focusing on lung fibrosis and viral infections. The text explicitly states that this information is being published because the preclinical studies 'may have a potentially significant impact on the future operations of the Issuer' (Powyższa informacja jest publikowana ze względu na fakt, iż przeprowadzenie badań przedklinicznych... może mieć potencjalnie istotny wpływ na przyszłą działalność Emitenta). This structure—a formal update on ongoing R&D activities that could materially affect the company's prospects—is characteristic of a regulatory disclosure, but it is not a full financial report (10-K, IR) or a standard earnings release (ER). Since it is a specific, material update on operations/research that doesn't fit the other specific categories (like DIRS, DIV, MANG), it falls best under the general Regulatory Filings category (RNS) or potentially a specific update category if one existed for R&D milestones. Given the provided definitions, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate classification for this type of material, non-financial, operational update that is not a presentation (IP) or a management discussion (MDA). The document length (2722 chars) is short, but it is providing substantive information, not just announcing another report, so RPA is less likely than RNS.
2021-02-02 Polish
Zawarcie aneksu do istotnej umowy kredytowej z BGK - Content (PL)
Capital/Financing Update Classification · 99% confidence The document text, written in Polish, discusses the signing of an annex (amendment) to a revolving credit agreement with Bank Gospodarstwa Krajowego (BGK). The key elements are the extension of a credit line (up to 2,000,000.00 PLN) and the purpose being 'managing the current financial liquidity of the Issuer.' This clearly relates to financing activities and capital structure management, rather than being a full annual report (10-K), an earnings release (ER), or a simple dividend announcement (DIV). The most appropriate category is Capital/Financing Update (CAP). The document length is very short (657 chars), but it describes the event itself (signing the annex), not just announcing that a financing document is available, thus making CAP more suitable than RPA or RNS.
2021-01-29 Polish
Decyzja PFR S.A. o udzieleniu pożyczki - Content (PL)
Capital/Financing Update Classification · 99% confidence The document is a formal announcement by the Management Board (Zarząd) of PHARMENA S.A. regarding receiving information from the Polish Development Fund (PFR) about the decision to grant the company a liquidity loan (pożyczki płynnościowej) up to 5,000,000 PLN under a government program ('Tarcza Finansowa'). This announcement details the purpose of the loan (financing current operations, working capital), the interest rate structure over four years, and the estimated repayment date (December 31, 2024). This clearly relates to the company securing new financing or changing its capital structure. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it describes a specific, material financing event.
2021-01-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.